Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Østergaard

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Arthritis and Rheumatism|June 25, 2011
Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosusChristoffer T Nielsen, Ole Østergaard, Christina Johnsen, et al.
Molecular & Cellular Proteomics : MCP|June 21, 2017
Paucimannose-Rich <i>N</i>-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune FunctionsIan Loke, Ole Østergaard, Niels H H Heegaard, et al.
Molecular & Cellular Proteomics : MCP|October 28, 2016
Quantitative Protein Profiling of Chlamydia trachomatis Growth Forms Reveals Defense Strategies Against Tryptophan StarvationOle Østergaard, Frank Follmann, Anja W Olsen, et al.
Proteomics|November 18, 2022
Differential ultracentrifugation enables deep plasma proteomics through enrichment of extracellular vesiclesAnders H Kverneland, Ole Østergaard, Kristina Bennet Emdal, et al.
Clinical Proteomics|April 14, 2017
A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosusChristoffer T Nielsen, Ole Østergaard, Niclas S Rasmussen, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's diseaseCasper Steenholdt, Morten Svenson, Klaus Bendtzen, et al.
American Journal of Nephrology|November 6, 2009
Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney diseaseBjarne Orskov, Malene L Borresen, Bo Feldt-Rasmussen, et al.
Scandinavian Journal of Gastroenterology|March 2, 2012
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center studyCasper Steenholdt, Akbar Molazahi, Mark Andrew Ainsworth, et al.
BMJ Open|December 20, 2014
Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialSine Schnoor Buhl, Casper Steenholdt, Jørn Brynskov, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 17, 2009
A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observationsSixten Borg, Ulf Persson, Tine Jess, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Arthritis and Rheumatism|June 25, 2011
Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosusChristoffer T Nielsen, Ole Østergaard, Christina Johnsen, et al.
Molecular & Cellular Proteomics : MCP|June 21, 2017
Paucimannose-Rich <i>N</i>-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune FunctionsIan Loke, Ole Østergaard, Niels H H Heegaard, et al.
Molecular & Cellular Proteomics : MCP|October 28, 2016
Quantitative Protein Profiling of Chlamydia trachomatis Growth Forms Reveals Defense Strategies Against Tryptophan StarvationOle Østergaard, Frank Follmann, Anja W Olsen, et al.
Proteomics|November 18, 2022
Differential ultracentrifugation enables deep plasma proteomics through enrichment of extracellular vesiclesAnders H Kverneland, Ole Østergaard, Kristina Bennet Emdal, et al.
Clinical Proteomics|April 14, 2017
A review of studies of the proteomes of circulating microparticles: key roles for galectin-3-binding protein-expressing microparticles in vascular diseases and systemic lupus erythematosusChristoffer T Nielsen, Ole Østergaard, Niclas S Rasmussen, et al.
Journal of Crohn'S & Colitis|January 21, 2012
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's diseaseCasper Steenholdt, Morten Svenson, Klaus Bendtzen, et al.
American Journal of Nephrology|November 6, 2009
Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney diseaseBjarne Orskov, Malene L Borresen, Bo Feldt-Rasmussen, et al.
Scandinavian Journal of Gastroenterology|March 2, 2012
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center studyCasper Steenholdt, Akbar Molazahi, Mark Andrew Ainsworth, et al.
BMJ Open|December 20, 2014
Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trialSine Schnoor Buhl, Casper Steenholdt, Jørn Brynskov, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|July 17, 2009
A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observationsSixten Borg, Ulf Persson, Tine Jess, et al.
Pageof 6